Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Research Funding » SBIR Funds in Hand, DxTerity Developing Radiation Toxicity Predictor Using Chemical Ligation Probes

SBIR Funds in Hand, DxTerity Developing Radiation Toxicity Predictor Using Chemical Ligation Probes

Nov 14, 2013
|
Madeleine Johnson
Premium

Molecular diagnostics company DxTerity Diagnostics was recently awarded a $280,000 Small Business Innovation Research contract from the National Cancer Institute to develop a test for susceptibility to radiation sickness during cancer treatment.

The gene expression-based system aims to identify patients likely to develop acute radiation side effects.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

More Details Wanted

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

And a Third

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

Glimpses of Viral Origins

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

PLOS Papers on Plasmodium Falciparum Populations, Scabies Molecular Diagnostics, More

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
25
Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

What's Popular?

In PCR

  1. Hologic Acquires European MDx Firm Diagenode for Approximately $159M

  2. Luminex Shares Surge on Rumor of Acquisition by DiaSorin

  3. FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

  4. Novacyt Obtains CE Mark for Extraction-Free COVID-19 PCR Test

  5. Mobidiag SARS-CoV-2, Influenza A/B, RSV Test Receives CE Mark

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.